The EGFR family consists of 4 receptor tyrosine kinases, EGFR (ERBB1), ERBB2 (HER2), ERBB3 (HER3) and ERBB4 (HER4). Recent reports revealed that the kinase domains of both EGFR (ERBB1) and ERBB2 gene were somatically mutated in human cancers, raising the possibility that the other ERBB members posse
Somatic mutations of GUCY2F, EPHA3, and NTRK3 in human cancers
β Scribed by Laura D. Wood; Eric S. Calhoun; Natalie Silliman; Janine Ptak; Steve Szabo; Steve M. Powell; Gregory J. Riggins; Tian-Li Wang; Hai Yan; Adi Gazdar; Scott E. Kern; Len Pennacchio; Kenneth W. Kinzler; Bert Vogelstein; Victor E. Velculescu
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 77 KB
- Volume
- 27
- Category
- Article
- ISSN
- 1059-7794
No coin nor oath required. For personal study only.
β¦ Synopsis
Tyrosine kinases are major regulators of signal transduction cascades involved in cellular proliferation and have important roles in tumorigenesis. We have recently analyzed the tyrosine kinase gene family for alterations in human colorectal cancers and identified somatic mutations in seven members of this gene family. In this study we have used highthroughput sequencing approaches to further evaluate this subset of genes for genetic alterations in other human tumors. We identified somatic mutations in GUCY2F, EPHA3, and NTRK3 in breast, lung, and pancreatic cancers. Our results implicate these tyrosine kinase genes in the pathogenesis of other tumor types and suggest that they may be useful targets for diagnostic and therapeutic intervention in selected patients.
π SIMILAR VOLUMES
Detection of K
The incidence (frequency of occurrence) and abundance (percentage of mutant out of total mtDNA population) of two different somatic mtDNA mutations in human skin were investigated in 44 subjects ranging from 19 to 87 years of age. Using quantitative allele-specific polymerase chain reaction (AS-PCR)
## Abstract Mutations in the __Bβraf__ gene have been reported in a number of human cancers, including melanoma and lung cancer. More than 80% of the reported Bβraf mutations were V599E; however, nonβV599E mutations have been frequently found in nonβsmall cell lung cancers as compared with melanoma